

May 27, 2016

The Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai – 400 001.

The National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex,
Bandra (E), Mumbai – 400 051

Scrip Code: 532531


Scrip Code: STAR

Dear Sirs,


Please find attached press release issued by the Company titled:


**“Strides Shasun receives USFDA Approval for
Metronidazole Tablets”**

Thanks & Regards,
For **STRIDES SHASUN LIMITED**



Badree Komandur
Group CFO & Company Secretary





Press Release

Friday, May 27, 2016

Strides Shasun Limited
Strides House, Bannerghatta Road,
Bangalore – 560076.

Strides Shasun receives USFDA Approval for Metronidazole Tablets

First Product Approval under GDUFA Regime

Bangalore, May 27, 2016 Strides Shasun Limited today announced that it has received approval from the United States Food & Drug Administration (USFDA) for **Metronidazole Tablets USP, 250 mg and 500 mg**. The product received approval in 17 months under the new GDUFA regime. The product is ready for immediate launch.

According to IMS data, the US market for Metronidazole Tablets USP, 250 mg and 500 mg is approximately USD 50 Million. The product will be manufactured at the company's Oral dosage facility at Bangalore and marketed by Strides in the US Market.

About Metronidazole

Metronidazole Tablets are indicated for treatment of wide variety of infections caused by particular types of bacteria and parasites.

About Strides Shasun Limited

Strides Shasun, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a vertically integrated global pharmaceutical Company headquartered in Bangalore. The Company has four business verticals, viz., Regulated Markets, Emerging Markets, Institutional Business and Pharmaceutical Services & Active Ingredients.

The Company has global manufacturing foot print with 14 manufacturing facilities spread across three continents including 6 US FDA approved facilities and 8 facilities for the emerging markets. The Company has three dedicated R&D facilities in India with global filing capabilities and a strong commercial footprint across 85 countries. Additional information is available at the Company's website at www.stridesarco.com



For further information, please contact:

<u>Strides Shasun</u> Badree Komandur, Group CFO +91 80 6784 0747 Vikesh Kumar +91 80 6784 0827 Kannan. N: +91 98450 54745 Sandeep Baid: +91 80 6784 0791	<u>PR Consultancy</u> Fortuna PR K Srinivas Reddy: +91 9000527213 srinivas@fortunapr.com K Priya: +91 9535425418 priya@fortunapr.com
---	---

